Background Cognitive dysfunction is one of the common symptoms in patients with major
depressive disorder (MDD). Repetitive transcranial magnetic stimulation (rTMS) and …

Background: Major depressive disorder is a psychiatric disorder that affects 4.4% of the
population worldwide. Although the majority of antidepressant drugs ameliorate depressive …

Background: Major Depressive disorder (MDD) is often accompanied by cognitive deficits,
involving attention, learning, memory and executive functioning. Selective Serotonin …

Rationale and objective Vortioxetine has been reported to exhibit a variety of
neurobiological functions and neuroprotective effects. In the present study, we aimed to …

Vortioxetine is a new drug against major depressive disorder with high affinity for a range of
different serotonergic targets in the central nervous system. Therapeutic drug monitoring is …

Objective Vortioxetine is a novel antidepressant whose safety, tolerability, and therapeutic
action have been supported by several studies. The present naturalistic study aimed to …

5-HT7 receptor antagonism has been shown to ameliorate ketamine-induced schizophrenia-
like deficits in extradimensional set-shifting using the attentional set-shifting task (ASST) …

Antidepressants often disrupt sleep. Vortioxetine, a multimodal antidepressant acting
through serotonin (5-HT) transporter (SERT) inhibition, 5-HT3, 5-HT7 and 5-HT1D receptor …

As ketamine is increasingly used as an effective antidepressant with rapid action, sustaining
its short-lived efficacy over a longer period of time using a schedule of repeated injections …

Background and Objectives: Elevated oxidative stress has been shown to play an important
role in the diagnosis and prognosis of stress and memory-related complications. Mukia …